FNNTF yields 0.11% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 5
Combined, FNNTF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FNNTF + JNJ for your $10,000?
flatexDEGIRO AG provides online brokerage and IT solutions in the areas of finance and financial technology services in Europe. It operates through Financial Services (FIN) and Technologies (TECH) segments. The FIN segment offers business-to-consumer online brokerage, business-to-business white-label banking, electronic securities settlement, custody account management, and other banking products and services. This segment also provides business process outsourcing solutions; technical transaction processing services; cash management services; and securities-backed lending services, as well as engages in treasury and investment activities. The TECH segment is involved in the development, production, distribution, and maintenance of software, hardware, and information technology infrastructure. This segment also provides a platform for banking operations; corporate payment products; and develops and operates Limit Order System, which monitors the limit orders of European brokers against the price feed of connected issuers. The company was formerly known as flatex AG and changed its name to flatexDEGIRO AG in October 2020. flatexDEGIRO AG was incorporated in 1999 and is based in Frankfurt am Main, Germany.
Full FNNTF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.